Pharmaceutical Industry

A Whole New Level of Junk Science

It’s no secret that the pharmaceutical industry trades in junk science. We’ve talked about how prescription drug companies distort research many times here on Health Beat, focusing on how companies fudge measures of drug effectiveness and generally control our knowledge...

United we disclose

The relationship between pharmaceutical makers and physicians has come under close scrutiny lately. In recent weeks Congressional leaders have accused Harvard physicians of failing to properly disclose large payments from drug companies; meanwhile, other reports have highlighted the industry ties of certain experts who helped write the American Society of Pediatrics’ new recommendations for managing childhood cholesterol. One way to facilitate greater transparency in biomedical research is to ...

This month in the promotional products industry

By next year, you cannot give out these promotional pens to healthcare clients. The promotional products industry seems to be taking a beating this month. In the first half of July, the Pharmaceutical Research and Manufacturers of America announced that it is prohibiting the “distribution of non-educational items (such as pens, mugs and other ‘reminder’ objects [...]

Possible Side Effects for Josh Lucas

Filed under: Other Drama Shows, OpEd, Casting, Reality-FreeJosh Lucas has been working in the film and TV industry since 1990, but he first came into my line of vision with 2002's Sweet Home Alabama, where he traded barbs with Reese Witherspoon. He shot to the top of my list with 2006's Glory Road, a great film in which he played Don Haskins, the Texas coach who shepherded an all-black team to the NCAA championship. Now I'll get to see more of Lucas, because he's been tapped to star in Possible ...

Catalent Announces New Vice President and General Manager for Its Printed Components Business

... for the pharmaceutical and healthcare industry, where he was President and CEO. Prior to that, he spent ten years at Alcoa, Inc. in positions of increasing responsibility, serving as General Manager, Vice President and General Manager and Vice ...

Roche Offers To Buy The Rest Of Genentech

The bid would allow the drugmaker, which already controls 56 percent of the biotech, to gain control of all the revenues generated by such big-selling meds as the Avastin and Herceptin treatments, as well as access to Genentech’s developing portfolio. “The pharmaceutical industry has changed fundamentally in the last 20 years, and the trend to consolidation [...]

Bayesian Approaches To Clinical Trials And Health-Care Evaluation Statistics In Practice

by David J. Spiegelhalter, Keith R. Abrams, and Jonathan P. Myles, "Bayesian Approaches To Clinical Trials And Health-Care Evaluation Statistics In Practice" Wiley | English | 2004 | ISBN: 0471499757 | 406 pages | pdf | 3 Mb David Spiegelhalter has recently joined the ranks of Isaac Newton, Charles Darwin and Stephen Hawking by becoming a fellow of the Royal Society. Originating from the Medical Research Council’s biostatistics unit, David has played a leading role in the Bristol heart surger...

Parexel International promotes Goldberg

Parexel International Corp., the Waltham pharmaceutical services company, said today that it promoted Mark A. Goldberg to chief operating officer. Goldberg, who joined Parexel in 1997, most recently worked as the president of clinical research services and perceptive informatics. "Dr. Goldberg has been an asset to Parexel's executive management team for more than 11 years," said Josef von Rickenbach, chairman and chief executive, in a statement. "His appointment as chief operating officer is in...

Psychiatrists' association faces drug funding probe

After a number of investigations into the under-disclosure of drug industry earnings by top psychiatry researchers, The New York Times reports that US Senator Charles Grassley is aiming at the mothership of American psychiatry, the American Psychiatric Association. Grassley is a Republican senator who has been pushing for transparency in the drug industry for some time and has particularly focused on drug payments to researchers and clinicians in recent months. He's been behind some recent high ...

Health 2.0 Accelerator

World's foremost popularizer of Health 2.0 (vs Health 3.0 or Health 4.0; we tend to think of ourselves as a Health 4.0 enterprise), Mr. Matthew Holt tells Medgadget: For several months there has been discussion amongst Health 2.0 companies about the concept of a Health 2.0 Accelerator. It started with Marty Tenenbaum's introduction of the concept in September 2007. It continued with the discussion at the San Diego meeting in March 2008. Since then conversations and meetings among a small group ...